| Literature DB >> 35734624 |
Yang Li1, Yun Liang1, Yao Deng1, Zhi-Wei Cai1, Ming-Jian Ma1, Long-Xiang Wang1, Meng Liu1, Hong-Wei Wang1, Chong-Yi Jiang2.
Abstract
BACKGROUND: The life-threatening complications following pancreatoduodenectomy (PD), intra-abdominal hemorrhage, and postoperative infection, are associated with leaks from the anastomosis of pancreaticoduodenectomy. Although several methods have attempted to reduce the postoperative pancreatic fistula (POPF) rate after PD, few have been considered effective. The safety and short-term clinical benefits of omental interposition remain controversial. AIM: To investigate the safety and feasibility of omental interposition to reduce the POPF rate and related complications in pancreaticoduodenectomy.Entities:
Keywords: Complication; Omental interposition; Pancreatic fistula; Pancreaticoduodenectomy
Year: 2022 PMID: 35734624 PMCID: PMC9160680 DOI: 10.4240/wjgs.v14.i5.482
Source DB: PubMed Journal: World J Gastrointest Surg
Figure 1Omental interposition was placed in front of the adjacent vessels and behind the anastomosis where the pancreas stump was fixed to the jejunum. 1: Liver; 2: Portal vein; 3: Hepatic artery; 4: Common bile duct; 5: Hepaticojejunostomy; 6: Gastrojejunostomy; 7: Celiac artery; 8: Pancreaticojejunostomy site; 9: Gastrojejunostomy. site; 10: Omental interposition; 11: Transverse colon.
Figure 2Application of the omental interposition in pancreaticoduodenectomy. A: The pedicled omental interposition was placed in front of the adjacent vessels (hepatic artery, portal vein, and gastroduodenal artery stump) and behind the pancreaticojejunostomy site; B: The right boundary of the omental interposition was the right margin of the inferior vena cava; C: The upper boundary of the omental interposition was the hepatogastric ligament; the omental interposition was fixed to the hepatic portal and hepatogastric ligament with several sutures to prevent postoperative mobilization; D: Postoperative computed tomography images. The omental interposition elevated the hepaticojejunostomy site and filled the potential cavity.
Comparisons of patients’ characteristics between the two groups
|
|
| |||||
|
|
|
|
|
|
| |
| Male/female | 79/48 | 44/25 | 0.919 | 46/23 | 44/25 | 0.721 |
| Age (yr) | 64.8 ± 10.5 | 62.1 ± 9.9 | 0.083 | 64.2 ± 9.5 | 62.1 ± 9.9 | 0.210 |
| BMI (mean ± SD, kg/m2) | 21.9 ± 3.0 | 22.0 ± 2.8 | 0.844 | 21.9 ± 3.2 | 22.0 ± 2.9 | 0.933 |
| ASA score, | 0.126 | 0.168 | ||||
| I | 65 (51.2) | 42 (60.9) | 34 (49.3) | 42 (60.9) | ||
| II | 60 (47.2) | 24 (34.8) | 34 (49.3) | 24 (34.8) | ||
| III | 2 (1.6) | 3 (4.3) | 1 (1.4) | 3 (4.3) | ||
| Serum ALB [ | 0.152 | 1.00 | ||||
| < 35 | 13 (10.2) | 12 (17.4) | 12 (17.4) | 12 (17.4) | ||
| ≥ 35 | 114 (89.8) | 57 (82.6) | 57 (82.6) | 57 (82.6) | ||
| Serum bilirubin (μmol/L) | 96.5 (17.9-107.0) | 20.5 (9.6-148.5) | 0.015 | 29.8 (12.4-153.7) | 20.5 (9.6-148.5) | 0.753 |
| Main pancreatic duct size [ | 0.080 | 0.173 | ||||
| < 3 | 57 (44.9) | 40 (58.0) | 32 (46.4) | 40 (58.0) | ||
| ≥ 3 | 70 (55.1) | 29 (42.0) | 37 (53.6) | 29 (42.0) | ||
| Operation method, | 0.005 | 0.708 | ||||
| LPD | 69 (54.3) | 19 (27.5) | 21 (30.4) | 19 (27.5) | ||
| OPD | 58 (45.7) | 50 (72.5) | 48 (69.6) | 50 (72.5) | ||
| Pathology, | 0.009 | 0.151 | ||||
| PDAC | 53 (41.7) | 25 (36.2) | 36 (52.2) | 25 (36.2) | ||
| Bile duct cancer | 10 (7.9) | 13 (18.8) | 4 (5.8) | 13 (18.8) | ||
| Ampulla of Vater cancer | 18 (14.2) | 15 (21.7) | 10 (14.5) | 15 (21.7) | ||
| Duodenal cancer | 11 (8.7) | 2 (2.9) | 2 (2.9) | 2 (2.9) | ||
| Other carcinoma | 19 (15.0) | 2 (2.9) | 3 (4.3) | 2 (2.9) | ||
| Benign tumor | 16 (12.6) | 12 (17.4) | 14 (20.3) | 12 (17.4) | ||
ALB: Albumin; ASA: American Society of Anesthesiologist score; BMI: Body mass index LPD: Laparoscopic pancreaticoduodenectomy; OPD: Open pancreaticoduodenectomy.
Comparisons of the postoperative outcomes between the two groups
|
|
| |||||
|
|
|
|
|
|
| |
| CR-POPF | 13 (10.2%) | 17 (24.6%) | 0.028 | 7 (10.1%) | 17 (24.6%) | 0.025 |
| Operation time (mean ± SD, min) | 388.3 ± 68.8 | 365.2 ± 75.0 | 0.031 | 392.6 ± 74.1 | 365.2 ± 75.0 | 0.033 |
| BF, | 2 (1.6) | 5 (7.2) | 0.041 | 1 (1.4) | 5 (7.2) | 0.208 |
| DGE, | 4 (3.1) | 6 (8.7) | 0.178 | 1 (1.4) | 6 (8.7) | 0.115 |
| PPH, | 1 (0.8) | 8 (11.6) | 0.002 | 1 (1.4) | 8 (11.6) | 0.016 |
| Intra-abdominal abscess, | 15 (11.8) | 12 (17.4) | 0.286 | 8 (11.6) | 12 (17.4) | 0.333 |
| Reoperation, | 3 (2.4) | 6 (8.7) | 0.096 | 2 (2.9) | 6 (8.7) | 0.274 |
| Mortality in 30 d, | 2 (1.6) | 5 (7.2) | 0.101 | 2 (2.9) | 5 (7.2) | 0.438 |
| Mortality related to POPF, | 1 (0.8) | 5 (7.2) | 0.038 | 1 (1.4) | 5 (7.2) | 0.210 |
| DFA1 around the HJ site (U/L) | 300.0 (74.3-893.0) | 599.8 (171.1-2064.7) | 0.002 | 200.0 (57.5-659.8) | 599.8 (171.1-2064.7) | 0.003 |
| DFA1 around the PJ site (U/L) | 546.8 (76.4-3094.0) | 350.0 (50.0-2577.4) | 0.255 | 325.0 (69.5-2972.5) | 350.0 (50.0-2577.4) | 0.951 |
| Duration until removal of the tube around the HJ site (d) | 7 (5-9) | 9 (7-14) | 0.000 | 8 (6-11) | 9 (7-14) | 0.115 |
| Duration until removing the tube around the PJ site (d) | 7 (6-11) | 10 (7-15) | 0.004 | 8 (6-12) | 10 (7-15) | 0.100 |
| Required blood transfusions, | 18 (14.2) | 20 (29.0) | 0.012 | 9 (13.0) | 20 (29.0) | 0.022 |
| Length of hospital stay (d) | 15 (11-22) | 21 (13-32) | 0.004 | 16 (12-24) | 21 (13-32) | 0.031 |
| Duration until restarting diet (d) | 6 (5-8) | 8 (6-15) | 0.001 | 7 (5-8) | 8 (6-15) | 0.048 |
BF: Biliary fistula; CR-POPF: Clinically relevant postoperative pancreatic fistula; DFA1: Drain fluid amylase obtained on the first postoperative day; DGE: Delayed gastric emptying; HJ: Hepaticojejunostomy; PJ: Pancreaticojejunostomy; PPH: Postpancreatectomy hemorrhage.
Figure 3Causes of death in the two groups.
Figure 4Differences between the two groups. A: Drain fluid amylase obtained on the first postoperative day (DFA1) before propensity score-matching (PSM); B: DFA1 after PSM.
The univariate and multivariate analyses of the propensity score-matched data to evaluate the risk factors associated with clinically relevant postoperative pancreatic fistula after pancreaticoduodenectomy
|
|
|
|
| |||
|
|
|
| ||||
| Age (mean ± SD, yr) | 63.5 ± 7.9 | 63.1 ± 10.1 | 0.829 | |||
| Sex, | 0.040 | |||||
| Male | 20 (83.3%) | 70 (61.4%) | 2.436 | 0.692-8.574 | 0.165 | |
| Female | 4 (16.7%) | 44 (38.6%) | Reference | |||
| Operation method, | 0.143 | |||||
| LPD | 4 (16.7%) | 36 (31.6%) | ||||
| OPD | 20 (83.3%) | 78 (68.4%) | ||||
| BMI (kg/m2) | 0.000 | |||||
| ≥ 23 | 18 (75.0%) | 33 (28.9%) | 6.094 | 2.021-18.374 | 0.001 | |
| < 23 | 6 (25.0%) | 81 (71.1%) | Reference | |||
| Serum bilirubin (μmol/L) | 96.6 (16.1-180.4) | 67 (13.8-111.2) | 0.185 | |||
| Serum ALB (g/L) | 0.843 | |||||
| ≥ 35 | 21 (87.5%) | 98 (86.0%) | ||||
| < 35 | 3 (12.5%) | 16 (14.0%) | ||||
| ASA score, | 0.122 | |||||
| Grade I | 11 (45.8%) | 66 (57.9%) | ||||
| Grade II | 11 (45.8%) | 47 (41.2%) | ||||
| Grade III | 2 (8.3%) | 1 (0.9%) | ||||
| Pathology, | 0.196 | |||||
| Malignancy | 23 (95.8%) | 96 (84.2%) | ||||
| Benign | 1 (4.2%) | 18 (15.8%) | ||||
| Omental interposition, | 0.025 | |||||
| Yes | 7 (29.2%) | 62 (54.4%) | Reference | |||
| No | 17 (70.8%) | 52 (45.6%) | 3.145 | 1.040-9.509 | 0.042 | |
| Operating time (mean ± SD, min) | 387.1±82.5 | 377.7±71.2 | 0.609 | |||
| HJ DFA1 (U/L) | 0.010 | |||||
| ≥ 1000 | 13 (54.2%) | 31 (27.2%) | 1.000 | 1.000-1.000 | 0.834 | |
| < 1000 | 11 (45.8%) | 83 (72.8%) | Reference | |||
| PJ DFA1 (U/L) | 0.115 | |||||
| ≥ 1000 | 13 (54.2%) | 42 (36.8%) | ||||
| < 1000 | 11 (45.8%) | 72 (63.2%) | ||||
| Main pancreatic duct size [ | 0.000 | |||||
| ≥ 3 | 3 (12.5%) | 64 (56.1%) | Reference | |||
| < 3 | 21 (87.5%) | 50 (43.9%) | 5.663 | 1.456-22.033 | 0.012 | |
ALB: Albumin; ASA: American Society of Anesthesiologist score; BMI: Body mass index; DFA1: Drain fluid amylase obtained on the first postoperative day; HJ: Hepaticojejunostomy; LPD: Laparoscopic pancreaticoduodenectomy; OPD: Open pancreaticoduodenectomy; PJ: Pancreaticojejunostomy.